Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2021 Results Earnings Conference Call May 11, 2021 4:30 PM ET Company Participants Melissa Forst - Argot Partners Dr. Briggs Morrison - Chief Executive Officer Daphne Karydas - Chief Financial Officer Michael Metzger - President, Chief Operating Officer Dr. Michael Meyers - Chief Medical Officer Dr. Peter Ordentlich - Chief Scientific Officer Conference Call Participants Philip Nadeau - Cowen & Company Bert Hazlett - BTIG Colleen Kusy - Baird Peter Lawson - Barc ...

Determined to realize a future in which people with cancer live longer and better than ever before Syndax §> 1Q21 EARNINGS PRESENTATION Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37708 Syndax Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 32-0162505 (State or Other J ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-37708 Syndax Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) (State or Other Jurisdiction of Incorporat ...

Determined to realize a future in which people with cancer live longer and better than ever before Syndax §> 4Q20 EARNINGS PRESENTATION Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking ...

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2020 Results Conference Call March 8, 2021 4:30 PM ET Company Participants Maghan Meyers - Argot Partners Dr. Briggs Morrison - Chief Executive Officer Daphne Karydas - Chief Financial Officer Michael Metzger - President, Chief Operating Officer Dr. Michael Meyers - Chief Medical Officer Dr. Peter Ordentlich - Chief Scientific Officer Conference Call Participants Philip Nadeau - Cowen & Company Bert Hazlett - BTIG Konstantinos Aprilakis - Stifel David Lebowitz - ...

Determined to realize a future in which people with cancer live longer and better than ever before Syndax 參 AXATILIMAB CONFERENCE CALL| DECEMBER 2020 Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify fo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) 35 Gatehouse Drive, Building D, Floor 3 Waltham, Massachusetts 02451 (Address of Principal Executive Offices) (Zip Code) or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 32-0162505 (State or Other Jurisdiction of Incorporation or Organization) For the transition period from to Commission File Number: 001-37708 Syndax Pharmaceuticals, Inc. (Exact Name of Registran ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37708 Syndax Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 32-0162505 (State or Other Ju ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37708 Syndax Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 32-0162505 (State or Other J ...